Seattle Genetics Inc. | Ownership
Companies that own Seattle Genetics Inc.
Baker Bros. Advisors LP
51,046,060
32.15%
1,470,651
25.48%
06/30/2018
PRIMECAP Management Co.
14,474,000
9.11%
33,418
0.75%
06/30/2018
Baillie Gifford & Co.
14,219,765
8.96%
-452,754
0.68%
06/30/2018
T. Rowe Price Associates, Inc.
10,571,099
6.66%
839,108
0.11%
06/30/2018
Wellington Management Co. LLP
10,408,424
6.56%
510,132
0.15%
06/30/2018
The Vanguard Group, Inc.
8,660,737
5.45%
136,180
0.02%
06/30/2018
BlackRock Fund Advisors
6,280,767
3.96%
-183,562
0.02%
06/30/2018
Capital Research & Management Co. (International Investors)
6,129,138
3.86%
17,028
0.49%
06/30/2018
Matrix Capital Management Co. LP
3,866,852
2.44%
73,852
7.94%
06/30/2018
SSgA Funds Management, Inc.
2,877,791
1.81%
-263,113
0.02%
06/30/2018
| Address |
21823 30th Drive SE
Bothell Washington 98021
United States
|
|
Employees
|
- |
| Website |
http://www.seattlegenetics.com |
| Updated |
07/08/2019 |
| Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. |
